a double-blind, placebo-controlled, randomized, clinical trial of the tlr-3 agonist rintatolimod in severe cases of chronic fatigue syndrome一项双盲、安慰剂对照、随机临床试验的tlr-3兴奋剂rintatolimod慢性疲劳综合症的严重病例.pdfVIP

a double-blind, placebo-controlled, randomized, clinical trial of the tlr-3 agonist rintatolimod in severe cases of chronic fatigue syndrome一项双盲、安慰剂对照、随机临床试验的tlr-3兴奋剂rintatolimod慢性疲劳综合症的严重病例.pdf

  1. 1、本文档共9页,可阅读全部内容。
  2. 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
a double-blind, placebo-controlled, randomized, clinical trial of the tlr-3 agonist rintatolimod in severe cases of chronic fatigue syndrome一项双盲、安慰剂对照、随机临床试验的tlr-3兴奋剂rintatolimod慢性疲劳综合症的严重病例

A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome 1 1 2 3 4 David R. Strayer *, William A. Carter , Bruce C. Stouch , Staci R. Stevens , Lucinda Bateman , Paul J. 5 6 7 Cimoch , Charles W. Lapp , Daniel L. Peterson , the Chronic Fatigue Syndrome AMP-516 Study Group , William M. Mitchell8* 1 Hemispherx Biopharma, Inc., Philadelphia, Pennsylvania, United States of America, 2 BCS Consulting, Philadelphia, Pennsylvania, United States of America, 3 University of the Pacific, Stockton, California, United States of America, 4 Fatigue Consultation Clinic, Salt Lake City, Utah, United States of America, 5 Center for Special Immunology, Fountain Valley, California, United States of America, 6 Hunter-Hopkins Center, Charlotte, North Carolina, United States of America, 7 Sierra Internal Medicine Associates, Incline Village, Nevada, United States of America, 8 Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America Abstract Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a severely debilitating disease of unknown pathogenesis consisting of a variety of symptoms including severe fatigue. The objective of the study was to examine the efficacy and safety of a TLR-3 agonist, rintatolimod (Poly I: C12U), in patients with debilitating CFS/ME. Methods and Findings: A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. T

您可能关注的文档

文档评论(0)

qianqiana + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:5132241303000003

1亿VIP精品文档

相关文档